RE: High price trade15 Sep 2022 12:07
A small molecule immunomodulator – ideally placed to address the significant unmet need in severe influenza
LPS human challenge trial commenced in July 2022 with initial early human efficacy data expected by year end 2022, learn more below
Succesful Phase I studies have been completed with safety and tolerability demonstrated
Selectively inhibits overwhelming inflammation in viral infections, such as influenza, while leaving the necessary immune functions intact to fight the infection. This contrasts with other immunomodulatory approaches, such as steroids, which affect both beneficial and damaging immune responses
Strain agnostic and unaffected by seasonal variants which is a significant advantage over treatments available on the market
Shelf stable oral drug making it an ideal stock piling candidate for both seasonal and pandemic outbreaks